Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Haruyoshi TomitaDepartment of Bacteriology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.ORCID 0000-0001-9969-2235
Funding
Astellas Foundation for Research on Metabolic DisordersEnvironmental Restoration and Conservation Agency JPMEERF25S21212Gunma Foundation for Medicine and Health Science Kambe Memorial Research AwardJapan Agency for Medical Research and Development JP23gm1610013Japan Agency for Medical Research and Development JP25fk0108664, JP25fk0108665, JP25fk0108712, JP25wm0225029Japan Agency for Medical Research and Development JP25fk0108665, JP25fk0108683, JP25fk0108712, JP25wm0225029, JP25gm1610003, JP25wm0125012, JP25wm0225054, JP25wm0325076Japan Agency for Medical Research and Development JP25fk0108665, JP25gm1610003Japan Agency for Medical Research and Development JP25fk0108665, JP25wm0225029Japan Agency for Medical Research and Development JP25wm0225029, JP25wm0125006Japanese Ministry of Health, Labor and Welfare 24KA1005Ministry of Education, Culture, Sports, Science and Technology 22K07052Ministry of Education, Culture, Sports, Science and Technology 22K07067Ministry of Education, Culture, Sports, Science and Technology 22K16368Ministry of Education, Culture, Sports, Science and Technology 22KK0058Ministry of Education, Culture, Sports, Science and Technology 23K06556Ministry of Education, Culture, Sports, Science and Technology 23KK0151Ministry of Education, Culture, Sports, Science and Technology 24K22200, 23K24126National Foundation for Science and Technology Development 108.02-2017.320Ohsumi Frontier Science Foundation (OFSF) Consortium for the Exploration of Microbial FunctionsTakeda Science Foundation
6 · The paper itself
Abstract
Vancomycin and linezolid are crucial for treating enterococcal infections. The global emergence of linezolid- and vancomycin-resistant enterococci is a growing concern. Enterococcal pELF-type linear plasmids, which confer both types of resistance, have been identified worldwide from clinical and environmental sources. Phylogenetic and structural analyses of pELF-type linear plasmids revealed that they diverged into two distinct lineages and evolved through the integration of circular plasmids. Our findings on this ongoing evolution advance the fundamental knowledge required for the future development of global and cross-sectoral surveillance.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ongoing independent evolution of linezolid and vancomycin-resistance pELF-type linear plasmids across the One Health spectrum. · full record | OpenQuestion